Adipose-derived Mesenchymal stem cell therapy for liver cirrhosis in mice
IFMBE Proceedings, ISSN: 1680-0737, Vol: 63, Page: 841-846
2018
- 1Citations
- 4Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Conference Paper Description
Mesenchymal stem cells (MSCs) are now an attractive source of cell therapy. We test the hypothesis that autologous adipose-derived mesenchymal stem cells ameliorate liver cirrhosis in mice. In this study, male Swiss mice were treated orally with olive oil or CCl4 for 11 weeks (3 times/week). Mouse adipose-derived stem cells (mADSCs) from adipose tissue of mice injuried by CCl4 for 3 weeks were cultured prior to transfer by tail vein injection. Hepatocyte-enriched markers were characterized using q-RT-PCR and MSC markers, hepatocyte-enriched proteins, and fibrosis were evaluated by flow cytometry and/or immunohistochemistry. Mice were divided into 4 groups (n = 10 each group): (1) normal, (2) cirrhotic, (3) cirrhotic/PBS, (4) cirrhotic/mADSCs (5 × 10 cells/mice). A separate set of mADSCs was labeled with CFDA to investigate cell homing. The results of in vitro evaluation on mADSCs showed that these cells are highly expression variety of hepatic-related genes such as Hgf, Alb, Ck18, Ck19, Cyp1a1, Afp, MUC1, Ldl receptor and strongly expression of Cyp1a1 and Hgf markers. Dose of 5 × 10 cells/animal improved AST/ALT/bilirubin/albumin index after 7 days of injection (p < 0.05); significantly down-regulate gene expression of TGF-beta 1 (14 fold less), procollagen (3 fold less) and nt5e (8 fold less), (p < 0.05). 100% mice improved histology index (HAI modified) and diminished the accumulation of collagen fibers after 21 days compared to 33.3% cirrhotic/PBS. mADSCs “home” to the liver tissue after 21 days.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85030851975&origin=inward; http://dx.doi.org/10.1007/978-981-10-4361-1_143; http://link.springer.com/10.1007/978-981-10-4361-1_143; http://link.springer.com/content/pdf/10.1007/978-981-10-4361-1_143; https://dx.doi.org/10.1007/978-981-10-4361-1_143; https://link.springer.com/chapter/10.1007/978-981-10-4361-1_143
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know